Cerenis Therapeutics Share Price CINNOBER BOAT
Equities
0RAG
FR0012616852
Biotechnology & Medical Research
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
- EUR | -.--% | -.--% | -.--% |
14/03 | Abionyx Pharma: to benefit from a 1ME grant from Bpifrance | CF |
11/03 | Abionyx: reduced net loss in 2023 | CF |
Sales 2023 | 4.6M 4.99M 416M | Sales 2024 * | 4.6M 4.99M 416M | Capitalization | 40.26M 43.66M 3.64B |
---|---|---|---|---|---|
Net income 2023 | -3M -3.25M -272M | Net income 2024 * | -6M -6.51M -543M | EV / Sales 2023 | 9.02 x |
Net cash position 2023 * | 100K 108K 9.05M | Net cash position 2024 * | 3.4M 3.69M 308M | EV / Sales 2024 * | 8.01 x |
P/E ratio 2023 * |
-8.93
x | P/E ratio 2024 * |
-7.81
x | Employees | - |
Yield 2023 * |
-
| Yield 2024 * |
-
| Free-Float | 68.01% |
Managers | Title | Age | Since |
---|---|---|---|
Cyrille Tupin
CEO | Chief Executive Officer | 48 | 01/07/01 |
Director of Finance/CFO | - | 01/08/01 | |
Renee Benghozi
CTO | Chief Tech/Sci/R&D Officer | - | 09/15/09 |
Members of the board | Title | Age | Since |
---|---|---|---|
Olivier Martinez
BRD | Director/Board Member | 54 | - |
Christian Chavy
BRD | Director/Board Member | 75 | 06/15/06 |
Cyrille Tupin
CEO | Chief Executive Officer | 48 | 01/07/01 |
EPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+11.91% | 118B | |
+11.60% | 106B | |
-4.68% | 24.28B | |
-0.82% | 21.96B | |
-10.12% | 18.16B | |
-42.12% | 16.37B | |
-17.47% | 15.56B | |
+2.77% | 13.63B | |
+34.58% | 12.27B |
- Stock Market
- Equities
- ABNX Stock
- 0RAG Stock